Compare · AZN vs GNLX
AZN vs GNLX
Side-by-side comparison of AstraZeneca PLC (AZN) and Genelux Corporation (GNLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and GNLX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $258.47B, about 2303.5x GNLX ($112.2M).
- Over the past year, AZN is up 95.4% and GNLX is down 58.4% - AZN leads by 153.8 points.
- AZN has hit the wire 18 times in the past 4 weeks while GNLX has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- AstraZeneca PLC
- Genelux Corporation
- Price
- $165.42-0.74%
- $2.42-2.02%
- Market cap
- $258.47B
- $112.2M
- 1M return
- -0.43%
- -4.35%
- 1Y return
- +95.37%
- -58.42%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2023
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 6
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- SEC Form 4 filed by AstraZeneca PLC
- AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- SEC Form 6-K filed by AstraZeneca PLC
- Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- SEC Form 6-K filed by AstraZeneca PLC
Latest GNLX
- Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
- President and CEO Zindrick Thomas sold $91,899 worth of shares (34,463 units at $2.67), decreasing direct ownership by 3% to 1,226,427 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $26,658 worth of shares (9,683 units at $2.75), decreasing direct ownership by 4% to 258,688 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph sold $28,112 worth of shares (10,257 units at $2.74), decreasing direct ownership by 3% to 318,480 units (SEC Form 4)
- Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Genelux Corporation
- Chief Technical Officer Cappello Joseph sold $1,924 worth of shares (653 units at $2.95), decreasing direct ownership by 0.20% to 328,737 units (SEC Form 4)
- President and CEO Zindrick Thomas sold $8,905 worth of shares (3,023 units at $2.95), decreasing direct ownership by 0.24% to 1,260,890 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $1,922 worth of shares (653 units at $2.94), decreasing direct ownership by 0.24% to 268,371 units (SEC Form 4)
- Attovia Therapeutics Appoints John W. Smither to Board of Directors